Alkermes Highlights Research on Psychiatry and Sleep Disorders at Neuroscience Education Institute Fall Congress
Alkermes plc (Nasdaq: ALKS) is presenting new data from its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, held from November 5-8, 2026, in Colorado Springs, Colo. The company is showcasing research on its approved medications, LYBALVI (olanzapine and samidorphan), ARISTADA (aripiprazole lauroxil), and LUMRYZ (sodium oxybate) extended-release oral suspension. Additionally, Alkermes is presenting data on alixorexton, an investigational oral, selective orexin 2 receptor (OX2R) agonist in development for narcolepsy types 1 and 2, and idiopathic hypersomnia. Key presentations include real-world assessments of LYBALVI's impact on acute care events in patients with schizophrenia or bipolar I disorder and comorbid alcohol use disorder, as well as research on the association between depression and disease burden in adults with narcolepsy and idiopathic hypersomnia. The company emphasizes its commitment to expanding evidence in neuroscience and improving care f...
